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LETTERS TO THE EDITORRole of Extracorporeal
Photopheresis (ECP)
in Treatment of
Steroid-Refractory Acute
Graft-versus-Host Disease
Recently, Pidala andAnasetti [1] presented a review
on glucocorticoid-refractory acute graft-versus-host
disease (aGVHD), which included options for salvage
therapies and future directions in this distinguished
scientific journal. Whereas salvage strategies with
antilymphocyte antibodies, immunotoxins, antitumor
necrosis factor alpha therapy, and immunomodulatory
agents were described in detail citing numerous studies
with sometimes small patient numbers both in the text
as well as in Tables 1 to 3, in the section on extracor-
poreal photopheresis (ECP) important studies are
missing [2-5]. Considering their results, complete
resolution (CR) rates would be as high as 73% [4]
and organ-specific CR rates would also increase in
skin manifestations up to 92% [4], in liver involvement
up to 100% [4], and in gastrointestinal (GI) manifesta-
tions up to 83% [3], respectively. The authors specifi-
cally mentioned conflicting data on CR rates in GI
manifestations of steroid-refractory aGVHD, citing
our pilot study with 21 patients [6]. In 2006, we pub-
lished results of a prospective phase II study on 38 pa-
tients with steroid-refractory (defined as progression
or no improvement of aGVHD after a minimum of 4
days of treatment with prednisone at $2 mg/kg body
weight [b.w.]) or steroid-dependent (defined as flare-
up of aGVHD during prednisone taper) aGVHD
and compared these with results obtained previously
in a pilot study with 21 patients [2]. As shown in
Table 1, patients of the phase II study had a signifi-
cantly shorter duration on steroids prior to the start
of ECP (15 versus 21 days, P5 .030), a shorter interval
from day 0 of hematopoietic stem cell transplantation
(HSCT) until the start of ECP (34 versus 41 days, P5
.0028), a lower median cumulative dose of steroids
given as first-line therapy (2.1 versus 3.9 mg/kg bw,
P 5 .0011), and a lower median steroid dose at start
of ECP (1.8 versus 2.6 mg/kg bw, P5 .010) compared
to patients of the pilot study. We could confirm high
response rates of cutaneous and liver manifestationsof steroid-refractory aGVHD in a larger patient num-
ber in the phase II study. Most impressively, however,
CR rates could be increased inpatientswithGI involve-
ment and grade IV aGVHD to 73% (8 of 11 patients)
and 60% (3 of 5 patients), respectively [2]. In univariate
analysis, a lower grade of aGVHD and less organs in-
volved both at the start of first-line steroid therapy as
well as at the start of ECP, and a lower cumulative
steroid dose prior to ECP significantly increased the
probability of CR to ECP. In logistic regression analy-
sis, only a later start of steroid medication after
HSCT and a lower grade of aGVHD at the initiation
of ECP were significantly associated with achieving a
CR of steroid-refractory aGVHD by ECP. Thus, ear-
lier initiation of ECP in the prospective phase II study
resulted in marked improvements in CR rates espe-
cially in patients with GI involvement and a grade IV
steroid-refractory aGVHD. Importantly, patients in the
phase II study received a more intense schedule of ECP
treatments as has also been reported by others [3,4,7]
consisting of 2 consecutive days at weekly intervals
instead of up to 2-week intervals in the pilot study.
In addition, we could confirm in the phase II
study a significantly lower treatmet-related mortality
(TRM, 14% versus 73%, P\ .0001) and a significantly
improved overall survival (OS, 59% versus 11%,
P\.0001) in patients achieving aCR toECPcompared
to others [2]. In univariate analysis a steroid dose below
1mg/kg b.w. 4weeks and below 0.5mg/kg b.w. 8weeks
after the start of ECPwere significantly associatedwith
lower TRM and improved OS, confirming the impor-
tance of the steroid-sparing effect of ECP on HSCT
outcome. Of note, in ECP-responding patients ste-
roids could be discontinued after amedian of 55 (range:
17-284) days after the start of ECP as shown inTable 1.
Furthermore, we would like to point out that the best
response to ECP was observed in our patients after
a median of 1.3 (range: 0.5-6) months of therapy, dem-
onstrating a short treatment durationwithout flare-ups
of aGVHD after discontinuation of ECP.
In conclusion, we present more complete data cur-
rently available on the use of ECP in steroid-refractory
aGVHD patients. Encouraged by recent exciting ani-
mal model studies on ECP [8] and aware of the fact
that few prospective studies with small patient num-
bers have been published, so far, we would like to
strongly encourage others to assess the impact of
ECP on HSCT outcome of aGVHD patients in
further well-designed studies.1747
Table 1. Comparison of Pilot Study [6] and Phase II Study [2] Using ECP for Second-Line Therapy of Steroid-Refractory Acute
Graft-versus-Host Disease
All Pilot Phase II
Number of patients 59 21 38
Median day of onset of aGVHD 17 19 17
Range 8-42 10-33 8-42
Median day of onset of steroids 19 21 19
Range 8-42 10-35 8-42
Grade of aGVHD at ECP
II 36 10 26
III 13 6 7
IV 10 5 5
Median days of steroids prior to ECP 17 21 15*
Range 4-49 9-49 4-43
Med. cum. steroid dose first-line (mg/kg bw) 2.8 3.9 2.1†
Range 2-10.4 2-10.4 2-6.5
Median interval D0-start of ECP (days) 37 41 34‡
Range 14-70 20-70 14-69
Med. dose of steroids at start of ECP (mg/kg b.w.) 2.1 2.6 1.8§
Range 0.7-10.4 1.1-10.4 0.7-2.3
% complete resolution of aGVHD
Grade II 86 100 85
Grade III 55 67 43
Grade IV 30 12 60
Skin 82 76 86
Liver 61 67 55
Gut 61 25 73
Best response after cycle (median) 4 4 4
Range 1-13 1-13 1-8
Best response after month (median) 1.3 1.7 1.2
Range 0.5-6 0.5-6 0.5-4.5
Med. days to D.C. steroids after start of ECP 55 53 56
Range 17-284 18-122 17-284
Med. steroid dose 4 weeks after start of ECP 0.9 1.1 0.7
Range (mg/kg b.w.) 0-5 0-5 0-2
Med. steroid dose 8 weeks after start of ECP 0.3 0.3 0.2
Range (mg/kg b.w.) 0-1.5 0-1.3 0-1.5
Med indicates median; b.w., body weight; cum, cumulative; D.C., discontinuation; aGVHD, acute graft-versus-host disease; ECP, extracorporeal photo-
pheresis.
Clarification: at the time of publication of the pilot study [6] 1 patient was still under ECP therapy, and thus reported as a nonresponder. In the com-
parison between the pilot study and phase II study [2] this patient had completed ECP therapy, and therefore the response rates for skin and GI involve-
ment are different than originally reported in the pilot study.
*P 5 .030.
†P 5 .0011.
‡P 5 .0028.
§P 5 .010.
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